A plausible therapeutic inhibitor of Mdm2 should have the following desirable properties: (a) a high binding affinity and specificity, (b) potent cellular activity in cancer cells with wild-type p53, and (c) a highly desirable pharmacokinetic profile [28]. The gene discussed is TP53; the disease is cancer.